抗体
穗蛋白
病毒学
Spike(软件开发)
生物
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
中和
突变体
冠状病毒
人口
2019年冠状病毒病(COVID-19)
免疫学
基因
医学
遗传学
疾病
传染病(医学专业)
管理
经济
病理
环境卫生
作者
Alina Baum,Benjamin O. Fulton,Elzbieta Wloga,Richard Copin,Kristen E. Pascal,Vincenzo Russo,Stephanie Giordano,Kathryn Lanza,Nicole Negron,Min Ni,Yi Wei,Gurinder S. Atwal,Andrew Murphy,Neil Stahl,George D. Yancopoulos,Christos A. Kyratsous
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2020-06-15
卷期号:369 (6506): 1014-1018
被引量:1356
标识
DOI:10.1126/science.abd0831
摘要
Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 (COVID-19) pandemic; however, concerns remain that mutations can yield antibody resistance. We investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails. These antibodies remain effective against spike variants that have arisen in the human population. However, novel spike mutants rapidly appeared after in vitro passaging in the presence of individual antibodies, resulting in loss of neutralization; such escape also occurred with combinations of antibodies binding diverse but overlapping regions of the spike protein. Escape mutants were not generated after treatment with a noncompeting antibody cocktail.
科研通智能强力驱动
Strongly Powered by AbleSci AI